Dr. Kendra Harris joined Tulane University School of Medicine’s Department of Radiation Oncology in July 2018, and is board-certified in radiation oncology and radiobiology.
Dr. Harris earned her medical degree from Johns Hopkins University School of Medicine and completed her residency in the Department of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins. She also completed a fellowship in patient safety at the Armstrong Institute for Patient Safety and Quality.
Prior to joining Tulane, Dr. Harris practiced at Orlando Health UF Health Cancer Center where she treated patients with proton therapy, photon therapy and high dose rate brachytherapy and served as PI for a number of clinical trials. She is also currently fulfilling a three-year appointment on the Metastatic/ Recurrent Task Force with the National Cancer Institute Coordinating Center for Clinical Trials.
Dr. Harris has been published in multiple journals on issues related to patient safety and is a member of the American Society for Therapeutic Radiology and Oncology (ASTRO).
In 2002, prior to medical school, she was selected as a Rhodes Scholar and completed a Master of Science (MSc) degree focused on health care policy at Oxford University, and in 2013, she earned the Frank L. Coulson Award for Clinical Excellence from the Johns Hopkins University School of Medicine.
Areas of Expertise (5)
Frank L. Coulson Award for Clinical Excellence (professional)
Johns Hopkins University School of Medicine
Rhodes Scholar (personal)
Johns Hopkins University: MD
Johns Hopkins University School of Medicine: Residency, Radiation Oncology & Molecular Radiation Sciences
Oxford University: MSc, Health Care Policy
- American Society for Therapeutic Radiology and Oncology (ASTRO)
- Metastatic/ Recurrent Task Force with the National Cancer Institute Coordinating Center for Clinical Trials
Media Appearances (3)
Musicians serenade city’s healthcare heroes in ‘Letters from the Porch’ concert series
News from Tulane online
At a time when many New Orleans musicians can’t work because of COVID-19 closures, Tulane University School of Medicine has partnered with local artists in a grass-roots effort to support the city’s cultural economy while also bringing moments of joy to healthcare workers on the front lines of the pandemic.
Behind the scenes: Tulane Cancer Center upgrades radiation oncology technology, facilities
WDSU-TV (NBC) New Orleans online
There's new state-of-the-art technology at Tulane Cancer Center in New Orleans.
Tulane's Health Center has upgraded its radiation oncology technology, facilities and capabilities by adding a new linear accelerator and CT simulator. There is also a renovated patient care area.
Stereotactic Body Radiotherapy Shows Potential in Oligometastatic Cancer
An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.
Harris KK, Fay A, Yan HG, Kunwar P, Socci ND, Pottabathini N, Juventhala RR, Djaballah H, Glickman MS
Novel imidazoline antimicrobial scaffold that inhibits DNA replication with activity against mycobacteria and drug resistant Gram-positive cocci. (2014)
Girgis HS, Harris K, Tavazoie S
Large mutational target size for rapid emergence of bacterial persistence. (2012)
Good TC, Harris KK, Ihunnah CA
Corticosteroids as potential mechanism regulating variability in reproductive success in monogamous oldfield mice. (2005)